The level of immunogenicity and efficacy of multi epitope DNA vaccines can be influenced by several factors. One critical factor is efficient in vivo delivery that allows for subsequent high-level expression of the encoded epitopes. We have designed a project that will allow for the systematic evaluation of several DNA vaccine delivery systems in rhesus macaques. using SIV CTL and HTL epitopes. This non-human primate model for HIV-1 was selected for use because of our current level of knowledge on the rhesus macaque MHC (Mamu) and the availability of characterized SIV-derived Mamu-restricted CTL and HTL epitopes. The program is organized into three phases: (1) design and in vitro optimization of multi- epitope DNA vaccines encoding the SIV-derived CTL and HTL epitopes (2) immunogenicity testing of a selected number of optimized vaccines formulated with up to four different DNA vaccine delivery systems in non-infected macaques, and (3) evaluation of one or two formulations in SIV-infected macaques that are concomitantly being treated with an anti- retroviral drug (PMPA). The immune responses of vaccinated macaques will be thoroughly characterized using multiple assays to allow for the measurement of CTL activity, numbers of circulating of epitope-specific CD8+ T cells and epitope-specific cytokine production. The levels of SIV will be followed in animals throughout the program to determine which vaccine formulation induces the most efficacious immune responses. The goal of the project is to identify a prototype DNA vaccine formulation that can be used as a model to design a comparable formulation to be testing in a clinical trial with a multi-epitope DNA vaccines based on HIV-1 derived epitopes. To increase the potential for a successful conclusion of the project, only delivery systems that have been used successfully in either vaccine or gene therapy clinical trials will be evaluated. Thus, the data obtained will support the design of clinical trial portion of the IPCP program.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
1P01AI048238-01
Application #
6352386
Study Section
Special Emphasis Panel (ZAI1-NBS-A (M1))
Project Start
2000-08-15
Project End
2004-07-31
Budget Start
Budget End
Support Year
1
Fiscal Year
2000
Total Cost
$208,270
Indirect Cost
Name
Idm Pharma, Inc.
Department
Type
DUNS #
018540968
City
Irvine
State
CA
Country
United States
Zip Code
92618
Walker, Leslie E; Vang, Lo; Shen, Xuefei et al. (2009) Design and preclinical development of a recombinant protein and DNA plasmid mixed format vaccine to deliver HIV-derived T-lymphocyte epitopes. Vaccine 27:7087-95
Gorse, Geoffrey J; Baden, Lindsey R; Wecker, Margaret et al. (2008) Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. Vaccine 26:215-23
Wilson, Cara C; Newman, Mark J; Livingston, Brian D et al. (2008) Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy. Clin Vaccine Immunol 15:986-94
Boritz, Eli; Rapaport, Eric L; Campbell, Thomas B et al. (2007) CD4+ T cell targeting of human immunodeficiency virus type 1 (HIV-1) peptide sequences present in vivo during chronic, progressive HIV-1 disease. Virology 361:34-44
Koeppe, John R; Campbell, Thomas B; Rapaport, Eric L et al. (2006) HIV-1-specific CD4+ T-cell responses are not associated with significant viral epitope variation in persons with persistent plasma viremia. J Acquir Immune Defic Syndr 41:140-8
McKinney, Denise M; Skvoretz, Rhonda; Livingston, Brian D et al. (2004) Recognition of variant HIV-1 epitopes from diverse viral subtypes by vaccine-induced CTL. J Immunol 173:1941-50
Boritz, Eli; Palmer, Brent E; Wilson, Cara C (2004) Human immunodeficiency virus type 1 (HIV-1)-specific CD4+ T cells that proliferate in vitro detected in samples from most viremic subjects and inversely associated with plasma HIV-1 levels. J Virol 78:12638-46
Wilson, Cara C; McKinney, Denise; Anders, Michelle et al. (2003) Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1. J Immunol 171:5611-23
Boritz, Eli; Palmer, Brent E; Livingston, Brian et al. (2003) Diverse repertoire of HIV-1 p24-specific, IFN-gamma-producing CD4+ T cell clones following immune reconstitution on highly active antiretroviral therapy. J Immunol 170:1106-16
Newman, Mark J; Livingston, Brian; McKinney, Denise M et al. (2002) T-lymphocyte epitope identification and their use in vaccine development for HIV-1. Front Biosci 7:d1503-15

Showing the most recent 10 out of 13 publications